Compare Stocks: ALIM, PCRX, AMPH, and HELP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALIM Alimera Sciences	$5.54	$5.55	$2.61 ▼ $5.65	$290.24M	1.25	376,318 shs	N/A
AMPH Amphastar Pharmaceuticals	$23.78	$20.84	$16.65 ▼ $29.52	$1.01B	0.92	379,230 shs	410,947 shs
HELP Cybin	$12.97	$9.97	$3.76 ▼ $14.35	$980.66M	0.63	1.43 million shs	1.15 million shs
PCRX Pacira BioSciences	$25.36	$25.48	$18.80 ▼ $27.66	$1.01B	0.26	473,133 shs	538,038 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALIM Alimera Sciences	0.00%	0.00%	0.00%	0.00%	0.00%
AMPH Amphastar Pharmaceuticals	0.00%	+2.59%	+13.73%	+20.65%	-15.25%
HELP Cybin	0.00%	+6.14%	+8.17%	+205.18%	+1,296,999,900.00%
PCRX Pacira BioSciences	0.00%	-3.76%	+10.26%	+11.52%	-6.49%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALIM Alimera Sciences	$5.54	$5.55	$2.61 ▼ $5.65	$290.24M	1.25	376,318 shs	N/A
AMPH Amphastar Pharmaceuticals	$23.78	$20.84	$16.65 ▼ $29.52	$1.01B	0.92	379,230 shs	410,947 shs
HELP Cybin	$12.97	$9.97	$3.76 ▼ $14.35	$980.66M	0.63	1.43 million shs	1.15 million shs
PCRX Pacira BioSciences	$25.36	$25.48	$18.80 ▼ $27.66	$1.01B	0.26	473,133 shs	538,038 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALIM Alimera Sciences	0.00%	0.00%	0.00%	0.00%	0.00%
AMPH Amphastar Pharmaceuticals	0.00%	+2.59%	+13.73%	+20.65%	-15.25%
HELP Cybin	0.00%	+6.14%	+8.17%	+205.18%	+1,296,999,900.00%
PCRX Pacira BioSciences	0.00%	-3.76%	+10.26%	+11.52%	-6.49%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALIM Alimera Sciences	0.00	N/A	N/A	N/A
AMPH Amphastar Pharmaceuticals	1.75	Reduce	$22.50	-5.38% Downside
HELP Cybin	3.00	Buy	$48.60	274.71% Upside
PCRX Pacira BioSciences	2.38	Hold	$29.83	17.64% Upside

Current Analyst Ratings Breakdown

Latest ALIM, PCRX, AMPH, and HELP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	PCRX Pacira BioSciences	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$28.00
9/1/2026	PCRX Pacira BioSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
8/20/2026	HELP Cybin	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $62.00
8/18/2026	AMPH Amphastar Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$20.00 ➝ $23.00
8/17/2026	PCRX Pacira BioSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
8/17/2026	PCRX Pacira BioSciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$30.00
8/7/2026	AMPH Amphastar Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$21.00 ➝ $20.00
8/7/2026	AMPH Amphastar Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$19.00 ➝ $20.00
8/5/2026	PCRX Pacira BioSciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$24.00 ➝ $25.00
8/5/2026	PCRX Pacira BioSciences	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $33.00
7/27/2026	HELP Cybin	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$16.00

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALIM Alimera Sciences	$99.68M	2.91	N/A	N/A	$0.88 per share	6.30
AMPH Amphastar Pharmaceuticals	$719.89M	1.41	$4.25 per share	5.59	$17.17 per share	1.38
HELP Cybin	N/A	N/A	N/A	N/A	$4.49 per share	N/A
PCRX Pacira BioSciences	$726.41M	1.39	$3.86 per share	6.57	$16.11 per share	1.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALIM Alimera Sciences	-$20.13M	-$1.57	N/A	26.38	N/A	-14.74%	-33.70%	-9.63%	N/A
AMPH Amphastar Pharmaceuticals	$98.09M	$1.69	14.07	9.18	4.58	10.76%	14.98%	6.96%	11/5/2026 (Estimated)
HELP Cybin	-$148M	-$3.02	N/A	N/A	N/A	N/A	-71.78%	-64.81%	N/A
PCRX Pacira BioSciences	$7.03M	$0.35	72.46	10.57	N/A	1.96%	9.68%	5.30%	11/5/2026 (Estimated)

Latest ALIM, PCRX, AMPH, and HELP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q1 2027	HELP Cybin	-$0.80	-$0.91	-$0.11	-$0.91	N/A	N/A
8/6/2026	Q2 2026	AMPH Amphastar Pharmaceuticals	$0.62	$0.91	+$0.29	$0.67	$179.92 million	$183.90 million
8/4/2026	Q2 2026	PCRX Pacira BioSciences	$0.6460	$0.73	+$0.0840	$0.12	$191.06 million	$192.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALIM Alimera Sciences	N/A	N/A	N/A	N/A	N/A
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HELP Cybin	N/A	N/A	N/A	N/A	N/A
PCRX Pacira BioSciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALIM Alimera Sciences	1.80	2.79	2.62
AMPH Amphastar Pharmaceuticals	0.79	2.40	1.71
HELP Cybin	N/A	10.97	10.97
PCRX Pacira BioSciences	0.54	5.04	3.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALIM Alimera Sciences	99.83%
AMPH Amphastar Pharmaceuticals	65.09%
HELP Cybin	17.94%
PCRX Pacira BioSciences	99.73%

Insider Ownership

Company	Insider Ownership
ALIM Alimera Sciences	31.40%
AMPH Amphastar Pharmaceuticals	29.60%
HELP Cybin	15.00%
PCRX Pacira BioSciences	6.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALIM Alimera Sciences	150	52.39 million	35.94 million	No Data
AMPH Amphastar Pharmaceuticals	1,976	42.54 million	29.95 million	Optionable
HELP Cybin	100	75.61 million	64.27 million	N/A
PCRX Pacira BioSciences	829	39.86 million	37.31 million	Optionable

ALIM, PCRX, AMPH, and HELP Headlines

Recent News About These Companies

Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Rating of "Hold" from Brokerages

September 11 at 4:28 AM | marketbeat.com

Leerink Partners Initiates Coverage on Pacira BioSciences (NASDAQ:PCRX)

September 11 at 1:54 AM | americanbankingnews.com

Leerink Partners initiates coverage of Pacira BioSciences at market perform

September 10, 2026 | msn.com

Pacira BioSciences (NASDAQ:PCRX) Now Covered by Leerink Partners

September 9, 2026 | marketbeat.com

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 9, 2026 | globenewswire.com

Public Employees Retirement System of Ohio Purchases New Position in Pacira BioSciences, Inc. $PCRX

September 9, 2026 | marketbeat.com

Wellington Management Group LLP Has $14.29 Million Holdings in Pacira BioSciences, Inc. $PCRX

September 8, 2026 | marketbeat.com

Legal & General Group Plc Buys Shares of 88,640 Pacira BioSciences, Inc. $PCRX

September 6, 2026 | marketbeat.com

296,880 Shares in Pacira BioSciences, Inc. $PCRX Purchased by Bank of New York Mellon Corp

September 4, 2026 | marketbeat.com

Man Group plc Buys New Holdings in Pacira BioSciences, Inc. $PCRX

September 1, 2026 | marketbeat.com

200,073 Shares in Pacira BioSciences, Inc. $PCRX Acquired by Empowered Funds LLC

September 1, 2026 | marketbeat.com

PDT Partners LLC Makes New Investment in Pacira BioSciences, Inc. $PCRX

August 27, 2026 | marketbeat.com

Foster & Motley Inc. Buys New Holdings in Pacira BioSciences, Inc. $PCRX

August 20, 2026 | marketbeat.com

Pacira BioSciences (NASDAQ:PCRX) Insider Jonathan Slonin Sells 3,040 Shares

August 19, 2026 | insidertrades.com

Rice Hall James & Associates LLC Purchases Shares of 93,396 Pacira BioSciences, Inc. $PCRX

August 19, 2026 | marketbeat.com

Pacira BioSciences (NASDAQ:PCRX) Insider Jonathan Slonin Sells 3,040 Shares of Stock

August 18, 2026 | marketbeat.com

Pacira BioSciences (NASDAQ:PCRX) Coverage Initiated at Truist Financial

August 17, 2026 | marketbeat.com

Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Recommendation of "Hold" from Brokerages

August 17, 2026 | marketbeat.com

Empowered Funds LLC Buys 49,171 Shares of Pacira BioSciences, Inc. $PCRX

August 17, 2026 | marketbeat.com

Pacira BioSciences (NASDAQ:PCRX) Lowered to "Buy" Rating by Wall Street Zen

August 16, 2026 | marketbeat.com

Is Pacira BioSciences (PCRX) Quietly Reframing Its Non‑Opioid Strategy Around PCRX‑201 Gene Therapy?

August 10, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALIM, PCRX, AMPH, and HELP Company Descriptions

Alimera Sciences NASDAQ:ALIM

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Amphastar Pharmaceuticals NASDAQ:AMPH

$23.78 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$24.08 +0.30 (+1.26%)

As of 09/11/2026 07:30 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Cybin NASDAQ:HELP

$12.97 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$13.28 +0.31 (+2.39%)

As of 07:22 AM Eastern

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a discovery-phase phenethylamine derivative to treat neuroinflammation and psychiatric conditions. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Pacira BioSciences NASDAQ:PCRX

$25.36 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$26.40 +1.04 (+4.10%)

As of 07:21 AM Eastern

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALIM, PCRX, AMPH, and HELP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALIM, PCRX, AMPH, and HELP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALIM, PCRX, AMPH, and HELP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALIM, PCRX, AMPH, and HELP Company Descriptions

Alimera Sciences NASDAQ:ALIM

Amphastar Pharmaceuticals NASDAQ:AMPH

Cybin NASDAQ:HELP

Pacira BioSciences NASDAQ:PCRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALIM, PCRX, AMPH, and HELP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALIM, PCRX, AMPH, and HELP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALIM, PCRX, AMPH, and HELP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALIM, PCRX, AMPH, and HELP Company Descriptions

Alimera Sciences NASDAQ:ALIM

Amphastar Pharmaceuticals NASDAQ:AMPH

Cybin NASDAQ:HELP

Pacira BioSciences NASDAQ:PCRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools